Search clinical trials for: RTH258

Total 22 results

Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration (FALCON)

Age-related Macular Degeneration

Germany, Switzerland
Novartis Pharmaceuticals

Completed

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Neovascular Age Related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Degeneration | Retinal Diseases | Wet Macular Degeneration

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration (SWIFT)

Neovascular Age-Related Macular Degeneration

France
Novartis Pharmaceuticals

Completed

A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration (OCTOPUS)

Neovascular Age Related Macular Degeneration

France
Novartis Pharmaceuticals

Completed

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. (IMAGINE)

Neovascular Age-related Macular Degeneration

Italy
Novartis Pharmaceuticals

Completed

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study (TALON Ext)

Neovascular Age-related Macular Degeneration

United States, Czechia, Italy, Taiwan, Australia, Israel, Belgium, France, Spain, Germany, Korea, Republic of, Portugal, Sweden, Netherlands, Malaysia, Switzerland
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy (CONDOR)

Proliferative Diabetic Retinopathy

China, India, Japan, Russian Federation, Turkey, Canada, United States, Australia, Korea, Republic of, Brazil, Philippines, Puerto Rico, Taiwan, Argentina, Chile, Mexico
Alcon Research

Completed

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KESTREL)

Diabetic Macular Edema

United States, Austria, Japan, Australia, Spain, Canada, Israel, Netherlands, Italy, United Kingdom, Portugal, Colombia, Puerto Rico, Argentina
Summit Therapeutics
Department of Health and Human Services

Terminated

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects (Ri-CoDIFy 3)

Clostridioides Difficile Infection

United States
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KITE)

Diabetic Macular Edema

Czechia, India, Russian Federation, Taiwan, Turkey, Lebanon, Denmark, Estonia, France, Germany, Hungary, Korea, Republic of, Latvia, Lithuania, Bulgaria, Norway, Belgium, Malaysia, Sweden, Slovakia, Singapore, Poland, Switzerland
Novartis Pharmaceuticals

Completed

To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema (KINGLET)

Diabetic Macular Edema

China
Novartis Pharmaceuticals

Withdrawn

Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (BUZZARD)

Diabetic Macula Edema
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)

Age-Related Macular Degeneration

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER)

Diabetic Macular Edema

United States, Hungary, Israel, Slovakia, Puerto Rico
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland
Alcon Research

Completed

Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 (HARRIER)

Choroidal Neovascularization | Neovascular Age-Related Macular Degeneration
Alcon Research

Completed

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 (HAWK)

Choroidal Neovascularization | Neovascular Age-Related Macular Degeneration

United States
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

Branch Retinal Vein Occlusion

China, Austria, Czechia, Russian Federation, Taiwan, United Kingdom, Canada, Japan, United States, France, Israel, Germany, Italy, Hong Kong, Spain, Denmark, Slovakia, Puerto Rico, Switzerland
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

Neovascular Age-related Macular Degeneration

United States, Puerto Rico
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)

Central Retinal Vein Occlusion

China, Czechia, Germany, Russian Federation, Turkey, United States, Australia, Canada, Spain, United Kingdom, Thailand, Israel, Netherlands, Italy, Hungary, France, Greece, Puerto Rico, Malaysia, Japan

Search clinical trials for: RTH258

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations